ArticleInternational journal of molecular sciences2023
Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Molecular subtyping and POLE mutation spectrum in endometrial carcinoma.The Indian journal of medical research · 2026Article
- Interpreting p53 IHC-TP53 NGS discordance in endometrial cancer: a mechanism-based diagnostic framework and clinical implications.Frontiers in oncology · 2026Article
- Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes.Pathology oncology research : POR · 2026Article
- ARID1A, β-Catenin and P53 Immunohistochemical Expression: Diagnostic Value in Endometrial Carcinoma and Premalignant Endometrial Lesions.Iranian journal of pathology · 2026Article
- PARP Inhibition in Colorectal Cancer-A Comparison of Potential Predictive Biomarkers for Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Prevalence of Mismatch Repair Gene Defects by Means of Immuno-histochemistry Staining for MMR Proteins in Endometrial Cancer.Journal of obstetrics and gynaecology of India · 2025Article
- New FIGO 2023 Staging System of Endometrial Cancer: An Updated Review on a Current Hot Topic.Geburtshilfe und Frauenheilkunde · 2025Article
- From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer.Cancers · 2025Review
- Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer.NPJ precision oncology · 2024Article
- Immunohistochemistry Markers in Ovarian and Fallopian Tube Neoplasms: a Comprehensive Review.Indian journal of surgical oncology · 2024Review
- Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohort.BMC cancer · 2024Article
- Article
- Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.Pathologica · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular algorithms may estimate the risk of recurrence and death for patients with endometrial cancer (EC) and may impact treatment decisions. To detect microsatellite instabilities (MSI) and p53 mutations, immunohistochemistry (IHC) and molecular techniques are used. To select the most appropriate method, and to have an accurate interpretation of their results, knowledge of the performance characteristics of these respective methods is essential. The objective of this study was to assess the diagnostic performance of IHC versus molecular techniques (gold standard). One hundred and thirty-two unselected EC patients were enrolled in this study. Agreement between the two diagnostic methods was assessed using Cohen's kappa coefficient. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of the IHC were calculated. For MSI status, the sensitivity, specificity, PPV and NPV were 89.3%, 87.3%, 78.1% and 94.1%, respectively. Cohen's kappa coefficient was 0.74. For p53 status, the sensitivity, specificity, PPV, and NPV were 92.3%, 77.1%, 60.0% and 96.4%, respectively. Cohen's kappa coefficient was 0.59. For MSI status, IHC presented a substantial agreement with the polymerase chain reaction (PCR) approach. For the p53 status, the moderate agreement observed between IHC and next generation sequencing (NGS) methods implies that they cannot be used interchangeably.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.